On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > COLUMN
COLUMN
- Maurer's Healthcare Insight (68)
October 17, 2005
- Maurer's Healthcare Insight (67)
September 26, 2005
- Maurer's Healthcare Insight (66)
August 8, 2005
- Maurer's Healthcare Insight (65)
July 11, 2005
- Maurer's Healthcare Insight (64)
June 13, 2005
- Maurer's Healthcare Insight (63)
May 30, 2005
- Maurer's Healthcare Insight (62)
April 25, 2005
- Maurer's Healthcare Insight (61)
March 28, 2005
- Maurer's Healthcare Insight (60)
March 14, 2005
- Maurer's Healthcare Insight (59)
December 6, 2004
- Maurer's Healthcare Insight (58)
November 8, 2004
- Maurer's Healthcare Insight (57)
October 11, 2004
- Maurer's Healthcare Insight (56)
September 13, 2004
- Maurer's Healthcare Insight (55)
July 26, 2004
- Maurer's Healthcare Insight (54)
May 17, 2004
- Maurer's Healthcare Insight (53)
April 19, 2004
- Maurer's Healthcare Insight (52)
March 22, 2004
- Maurer's Healthcare Insight (51)
March 1, 2004
- Maurer's Healthcare Insight (50)
February 16, 2004
- Maurer's Healthcare Insight (49)
January 26, 2004
ページ
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…